Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
UBE2J1 CRISPR/Cas9 KO Plasmid (h): sc-405892
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- UBE2J1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the UBE2J1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: UBE2J1 Antibody (B-6): sc-377002
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UBE2J1 CRISPR/Cas9 KO Plasmid (h) | sc-405892 | 20 µg | $397.00 |
Overview
UBE2J1 encodes an endoplasmic reticulum (ER)-anchored E2 ubiquitin-conjugating enzyme that cooperates with E3 ligases to ubiquitinate misfolded or regulated substrates for proteasomal degradation. It functions in ER-associated degradation (ERAD), linking protein quality control to ubiquitin–proteasome system activity and maintenance of ER homeostasis during cellular stress. Through modulation of proteostasis, UBE2J1 impacts pathways connected to unfolded protein response signaling, secretory protein maturation, and turnover of membrane-associated proteins. Dysregulation of ERAD components, including UBE2J1, is relevant to research on disorders characterized by proteotoxic stress and altered ubiquitin-mediated protein turnover.
UBE2J1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the UBE2J1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the UBE2J1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the UBE2J1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish UBE2J1 protein expression.
This CRISPR knockout system enables efficient generation of UBE2J1-deficient cell models for investigation of UBE2J1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting UBE2J1 exon(s) critical for UBE2J1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple UBE2J1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by UBE2J1 CRISPR/Cas9 KO Plasmid (h) and UBE2J1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the UBE2J1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by UBE2J1 HDR Plasmid (h) and UBE2J1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by UBE2J1 homology arms to support homology-directed repair at defined UBE2J1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.